文献速递瓣膜外科

65岁及以上退行性二尖瓣反流行二尖瓣修复与置换的比较

Mitral Repair vs Replacement for Degenerative Mitral Regurgitation in Patients Aged ≥65 Years.
PubMed 文献 · Ann Thorac Surg · 2023-06-10

该研究纳入1985年至2005年663例65岁及以上黏液瘤样退行性二尖瓣疾病患者,行首次孤立二尖瓣修复(434例)或置换(229例),采用倾向性评分匹配平衡变量。匹配患者中修复组围术期死亡率为3.9%,置换组为10.9%(P=0.004);修复组中位生存11.3年,置换组6.9年(P<0.001)。结论认为修复相比置换的生存获益持续患者终生。

要点

  • 匹配患者中围术期死亡率修复组3.9%(9/229),置换组10.9%(25/229),P=0.004。
  • 匹配患者中位生存修复组11.3年,置换组6.9年,P<0.001。
  • 修复组10年、20年生存率分别为54.6%、11.0%,置换组为34.2%、3.7%。

核心结论

  • 研究表明,尽管老年人群常合并多种疾病,孤立二尖瓣修复相比置换的生存获益持续患者终生。

研究设计与样本

  • 回顾性分析1985年1月至2005年12月663例65岁及以上黏液瘤样退行性二尖瓣疾病患者,行首次孤立二尖瓣修复(n=434)或置换(n=229),采用倾向性评分匹配平衡变量。

主要发现

  • 随访完整率修复组99.1%,置换组99.6%。
  • 匹配患者中围术期死亡率修复组3.9%(9/229),置换组10.9%(25/229),P=0.004。
  • 匹配患者29年随访生存估计(95%置信限):修复组10年54.6%(48.0%,61.1%),20年11.0%(6.8%,15.2%);置换组10年34.2%(27.7%,40.7%),20年3.7%(1%,6.4%)。
  • 匹配患者中位生存(95%置信限)修复组11.3年(9.6,12.2年),置换组6.9年(6.3,8.0年),P<0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of mitral valve repair vs replacement are well documented. However, survival benefits in the elderly population are more controversial. In this novel lifetime analysis, we hypothesize that survival benefits for valve repair vs replacement in the elderly are sustained throughout the patient's lifetime. METHODS: From January 1985 through December 2005, 663 patients, aged ≥65 years with myxomatous degenerative mitral valve disease underwent primary isolated mitral valve repair (n = 434) or replacement (n = 229). Propensity score matching was used to balance variables potentially related to outcome. RESULTS: Follow-up was complete in 99.1% of mitral repair and 99.6% of mitral replacement patients. In matched patients, perioperative mortality was 3.9% (9 of 229) for repair and 10.9% (25 of 229) for replacement (P = .004). Survival estimates (95% confidence limits) from 29-year follow-up for matched patients were 54.6% (48.0%, 61.1%) and 11.0% (6.8%, 15.2%) at 10 years and 20 years for repair patients, and 34.2% (27.7%, 40.7%) and 3.7% (1%, 6.4%) for replacement patients, respectively. Median survival (95% confidence limits) was 11.3 years (9.6, 12.2 years) for repair patients compared with 6.9 years (6.3, 8.0 years) for replacement patients (P < .001). CONCLUSIONS: This study demonstrates that although the elderly population is prone to multiple comorbidities, survival benefits of isolated mitral valve repair vs replacement are sustained throughout the patient's lifetime.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kurlansky PA, Traad EA, Ebra G, et al. Mitral Repair vs Replacement for Degenerative Mitral Regurgitation in Patients Aged ≥65 Years. Ann Thorac Surg. 2023. PMID: 37308067. doi:10.1016/j.athoracsur.2023.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。